Dougherty & Co restated their buy rating on shares of BioTelemetry, Inc. (NASDAQ:BEAT) in a research note published on Wednesday. The firm currently has a $40.00 price target on the medical research company’s stock.

Other equities research analysts have also issued research reports about the stock. Sidoti reaffirmed a buy rating and set a $49.00 target price (up previously from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. BidaskClub lowered shares of BioTelemetry from a strong-buy rating to a buy rating in a report on Tuesday, July 25th. Lake Street Capital reaffirmed a buy rating and set a $50.00 target price (up previously from $35.00) on shares of BioTelemetry in a report on Friday, July 14th. Zacks Investment Research raised shares of BioTelemetry from a hold rating to a strong-buy rating and set a $39.00 target price for the company in a report on Friday, August 11th. Finally, Benchmark Co. upped their target price on shares of BioTelemetry from $38.00 to $44.00 and gave the stock a buy rating in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $42.86.

BioTelemetry (BEAT) traded down $0.40 during trading hours on Wednesday, reaching $24.30. 546,700 shares of the company’s stock were exchanged, compared to its average volume of 583,778. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.60 and a quick ratio of 1.91. The firm has a market capitalization of $787.51, a PE ratio of 33.29, a PEG ratio of 1.38 and a beta of 0.58. BioTelemetry has a 52 week low of $17.27 and a 52 week high of $39.20.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, November 7th. The medical research company reported $0.16 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. The business had revenue of $81.02 million for the quarter, compared to analysts’ expectations of $82.10 million. During the same period in the previous year, the company earned $0.21 EPS. BioTelemetry’s quarterly revenue was up 52.7% compared to the same quarter last year. equities research analysts predict that BioTelemetry will post 0.86 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “BioTelemetry, Inc. (BEAT) Given “Buy” Rating at Dougherty & Co” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/biotelemetry-inc-beat-given-buy-rating-at-dougherty-co/1698522.html.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Winslow Evans & Crocker Inc. purchased a new stake in shares of BioTelemetry in the third quarter valued at about $109,000. Pinebridge Investments L.P. grew its holdings in shares of BioTelemetry by 2.0% in the second quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock valued at $126,000 after purchasing an additional 75 shares during the period. Victory Capital Management Inc. grew its holdings in shares of BioTelemetry by 17.6% in the second quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock valued at $140,000 after purchasing an additional 626 shares during the period. Dubuque Bank & Trust Co. purchased a new stake in shares of BioTelemetry in the second quarter valued at about $142,000. Finally, US Bancorp DE purchased a new stake in shares of BioTelemetry in the second quarter valued at about $145,000. 77.76% of the stock is owned by hedge funds and other institutional investors.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.